TY - JOUR
T1 - Development of an immunodeficient pig model allowing long-term accommodation of artificial human vascular tubes
AU - Itoh, Manabu
AU - Mukae, Yosuke
AU - Kitsuka, Takahiro
AU - Arai, Kenichi
AU - Nakamura, Anna
AU - Uchihashi, Kazuyoshi
AU - Toda, Shuji
AU - Matsubayashi, Kumika
AU - Oyama, Jun ichi
AU - Node, Koichi
AU - Kami, Daisuke
AU - Gojo, Satoshi
AU - Morita, Shigeki
AU - Nishida, Takahiro
AU - Nakayama, Koichi
AU - Kobayashi, Eiji
N1 - Publisher Copyright:
© 2019, The Author(s).
PY - 2019/12/1
Y1 - 2019/12/1
N2 - Before they are used in the clinical setting, the effectiveness of artificially produced human-derived tissue-engineered medical products should be verified in an immunodeficient animal model, such as severe combined immunodeficient mice. However, small animal models are not sufficient to evaluate large-sized products for human use. Thus, an immunodeficient large animal model is necessary in order to properly evaluate the clinical efficacy of human-derived tissue-engineered products, such as artificial grafts. Here we report the development of an immunodeficient pig model, the operational immunodeficient pig (OIDP), by surgically removing the thymus and spleen, and creating a controlled immunosuppressive protocol using a combination of drugs commonly used in the clinical setting. We find that this model allows the long-term accommodation of artificial human vascular grafts. The development of the OIDP is an essential step towards a comprehensive and clinically relevant evaluation of human cell regeneration strategies at the preclinical stage.
AB - Before they are used in the clinical setting, the effectiveness of artificially produced human-derived tissue-engineered medical products should be verified in an immunodeficient animal model, such as severe combined immunodeficient mice. However, small animal models are not sufficient to evaluate large-sized products for human use. Thus, an immunodeficient large animal model is necessary in order to properly evaluate the clinical efficacy of human-derived tissue-engineered products, such as artificial grafts. Here we report the development of an immunodeficient pig model, the operational immunodeficient pig (OIDP), by surgically removing the thymus and spleen, and creating a controlled immunosuppressive protocol using a combination of drugs commonly used in the clinical setting. We find that this model allows the long-term accommodation of artificial human vascular grafts. The development of the OIDP is an essential step towards a comprehensive and clinically relevant evaluation of human cell regeneration strategies at the preclinical stage.
UR - http://www.scopus.com/inward/record.url?scp=85065961308&partnerID=8YFLogxK
U2 - 10.1038/s41467-019-10107-1
DO - 10.1038/s41467-019-10107-1
M3 - 学術論文
C2 - 31113942
AN - SCOPUS:85065961308
SN - 2041-1723
VL - 10
JO - Nature Communications
JF - Nature Communications
IS - 1
M1 - 2244
ER -